Phosphodiesterase genes and antidepressant treatment response: A review

References

• Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289: 3095–105
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Health, United States, 2007. With Chartbook on Trends in the Health of Americans, Hyattsville, , MD: 2007.
   Google Scholar
• Kennedy SH, Giacobbe P. Treatment resistant depression—advances in somatic therapies. Ann Clin Psychiatry. 2007; 19: 279–87
   PubMedGoogle Scholar
• Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry 2007; 68 Suppl 10: 8–10
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163: 28–40
   PubMed Web of Science ®Google Scholar
• Murphy GM, Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry. 2003; 160: 1830–5
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008; 63: 699–704
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008; 33: 2300
   Google Scholar
• Hebb AL, Robertson HA. Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol. 2007; 7: 86–92
   Google Scholar
• Halene TB, Siegel SJ. PDE inhibitors in psychiatry—future options for dementia, depression and schizophrenia?. Drug Discov Today. 2007; 12: 870–8
   PubMed Web of Science ®Google Scholar
• Giembycz MA, Smith SJ. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?. Curr Pharm Des. 2006; 12: 3207–20
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005; 10: 1503–19
   PubMed Web of Science ®Google Scholar
• Perry MJ, Higgs GA. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol. 1998; 2: 472–81
   Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006; 109: 366–98
   PubMed Web of Science ®Google Scholar
• Tanis KQ, Duman RS. Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med. 2007; 39: 531–44
   Web of Science ®Google Scholar
• Teng FY, Tang BL. Axonal regeneration in adult CNS neurons—signaling molecules and pathways. J Neurochem. 2006; 96: 1501–8
   PubMed Web of Science ®Google Scholar
• Nair A, Vaidya VA. Cyclic AMP response element binding protein and brain-derived neurotrophic factor: molecules that modulate our mood?. J Biosci. 2006; 31: 423–34
   Google Scholar
• Soderling TR, Corbin JD, Park CR. Regulation of adenosine 3′,5′-monophosphate-dependent protein kinase. II. Hormonal regulation of the adipose tissue enzyme. J Biol Chem. 1973; 248: 1822–9
   PubMed Web of Science ®Google Scholar
• Jarnaess E, Tasken K. Spatiotemporal control of cAMP signalling processes by anchored signalling complexes. Biochem Soc Trans. 2007; 35: 931–7
   PubMedGoogle Scholar
• Su YF, Johnson GL, Cubeddu L, Leichtling BH, Ortmann R, Perkins JP. Regulation of adenosine 3′:5′-monophosphate content of human astrocytoma cells: mechanism of agonist-specific desensitization. J Cyclic Nucleotide Res. 1976; 2: 271–85
   Google Scholar
• Barber R, Clark RB, Kelly LA, Butcher RW. A model of desensitization in intact cells. Adv Cyclic Nucleotide Res. 1978; 9: 507–16
   Google Scholar
• Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 1990; 4: 2881–9
   PubMed Web of Science ®Google Scholar
• Lohse MJ. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta. 1993; 1179: 171–88
   PubMed Web of Science ®Google Scholar
• Conti M, Nemoz G, Sette C, Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 1995; 16: 370–89
   PubMed Web of Science ®Google Scholar
• Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58: 488–520
   PubMed Web of Science ®Google Scholar
• Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov. 2006; 5: 660–70
   PubMed Web of Science ®Google Scholar
• Charbonneau H, Prusti RK, LeTrong H, Sonnenburg WK, Mullaney PJ, Walsh KA, et al. Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases. Proc Natl Acad Sci U S A. 1990; 87: 288–92
   Google Scholar
• Aravind L, Ponting CP. The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci. 1997; 22: 458–9
   PubMed Web of Science ®Google Scholar
• Letunic I, Copley RR, Pils B, Pinkert S, Schultz J, Bork P. SMART 5: domains in the context of genomes and networks. Nucleic Acids Res. 2006;34( Database issue):D257–60.
   PubMed Web of Science ®Google Scholar
• Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, et al. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A. 1996; 93: 10477–82
   PubMed Web of Science ®Google Scholar
• Martinez SE, Beavo JA, Hol WG. GAF Domains: Two-billion-year-old molecular switches that bind cyclic nucleotides. Mol Interv. 2002; 2: 317–23
   Google Scholar
• Zoraghi R, Corbin JD, Francis SH. Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. Mol Pharmacol. 2004; 65: 267–78
   PubMed Web of Science ®Google Scholar
• Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A. 1999; 96: 7071–6
   PubMed Web of Science ®Google Scholar
• Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, et al. Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci U S A. 2000; 97: 12891–5
   Google Scholar
• Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem. 2000; 275: 31469–79
   PubMed Web of Science ®Google Scholar
• Weeks JL, 2nd, Zoraghi R, Francis SH, Corbin JD. N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry. 2007; 46: 10353–64
   Google Scholar
• Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A. 2000; 97: 3702–7
   PubMed Web of Science ®Google Scholar
• Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996; 16: 2365–72
   PubMed Web of Science ®Google Scholar
• Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest. 2002; 121: 192S–6S
   PubMed Web of Science ®Google Scholar
• Suda S, Nibuya M, Ishiguro T, Suda H. Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J Neurochem. 1998; 71: 1554–63
   Google Scholar
• Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci. 1999; 19: 610–8
   Google Scholar
• Ye Y, Jackson K, O'Donnell JM. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem. 2000; 74: 1257–62
   Google Scholar
• Miro X, Perez-Torres S, Artigas F, Puigdomenech P, Palacios JM, Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology. 2002; 43: 1148–57
   Google Scholar
• D'Sa C, Eisch AJ, Bolger GB, Duman RS. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci. 2005; 22: 1463–75
   PubMed Web of Science ®Google Scholar
• Cho CH, Cho DH, Seo MR, Juhnn YS. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp Mol Med. 2000; 32: 110–4
   PubMed Web of Science ®Google Scholar
• Dlaboga D, Hajjhussein H, O'Donnell JM. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res. 2006; 1096: 104–12
   Google Scholar
• Fujita M, Imaizumi M, D'Sa C, Zoghbi SS, Crescenzo MS, Hong J, et al. In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant administration. Synapse. 2007; 61: 78–86
   Google Scholar
• Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology. 2002; 27: 587–95
   PubMedGoogle Scholar
• Kurt M, Bilge SS, Aksoz E, Kukula O, Celik S, Kesim Y. Effect of sildenafil on anxiety in the plus-maze test in mice. Pol J Pharmacol. 2004; 56: 353–7
   PubMedGoogle Scholar
• Hebb AL, Robertson HA, Denovan-Wright EM. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. Eur Neuropsychopharmacol. 2008; 18: 339–63
   Google Scholar
• Itoh T, Abe K, Tokumura M, Horiuchi M, Inoue O, Ibii N. Different regulation of adenylyl cyclase and rolipram-sensitive phosphodiesterase activity on the frontal cortex and hippocampus in learned helplessness rats. Brain Res. 2003; 991: 142–9
   Google Scholar
• Itoh T, Tokumura M, Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur J Pharmacol. 2004; 498: 135–42
   PubMed Web of Science ®Google Scholar
• Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007; 18: 391–418
   PubMed Web of Science ®Google Scholar
• Kaster MP, Rosa AO, Santos AR, Rodrigues AL. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int J Neuropsychopharmacol. 2005; 8: 601–6
   PubMed Web of Science ®Google Scholar
• Dhir A, Kulkarni SK. Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology. 2007; 80: 239–43
   PubMedGoogle Scholar
• Dhir A, Kulkarni SK. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol. 2007; 568: 177–85
   PubMed Web of Science ®Google Scholar
• Volke V, Wegener G, Vasar E. Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharmacol. 2003; 54: 653–60
   Google Scholar
• Brink CB, Clapton JD, Eagar BE, Harvey BH. Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm. 2008; 115: 117–25
   PubMedGoogle Scholar
• Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, et al. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology. 2008; 33: 1611–23
   PubMed Web of Science ®Google Scholar
• Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006; 51: 374–85
   PubMed Web of Science ®Google Scholar
• Siuciak JA, McCarthy SA, Chapin DS, Martin AN. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 2008; 197: 115–26
   PubMedGoogle Scholar
• Perez-Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat. 2000; 20: 349–74
   PubMed Web of Science ®Google Scholar
• Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 1984; 17: 188–90
   PubMed Web of Science ®Google Scholar
• Horowski R, Satre-Y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterases inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res. 1985; 38: 23–9
   Web of Science ®Google Scholar
• Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci. 1988; 238: 2–6
   PubMedGoogle Scholar
• Laux G, Becker T, Kuhne G, Lesch KP, Riederer P, Beckmann H. Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level. Pharmacopsychiatry. 1988; 21: 378–9
   Google Scholar
• Clinical Trials.gov, M0952 in patients with mild-to-moderate Alzheimer's Disease, www.clinicaltrials.gov/ct2/show/NCT00362024 (accessed 10 August 2008).
   Google Scholar
• O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci. 2004; 25: 158–63
   PubMed Web of Science ®Google Scholar
• Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002; 110: 1045–52
   PubMed Web of Science ®Google Scholar
• Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005; 112: 2980–5
   PubMed Web of Science ®Google Scholar
• Richalet JP, Gratadour P, Robach P, Pham I, Dechaux M, Joncquiert-Latarjet A, et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med. 2005; 171: 275–81
   PubMed Web of Science ®Google Scholar
• Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A. 2008; 105: 7028–33
   PubMed Web of Science ®Google Scholar
• Rosen RC, Jackson G, Kostis JB. Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep. 2006; 7: 490–6
   PubMedGoogle Scholar
• Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Suppiramaniam V, Dhanasekaran M. Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep. 2007; 59: 150–63
   PubMed Web of Science ®Google Scholar
• Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng LJ, et al. Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2006; 67: 240–6
   PubMed Web of Science ®Google Scholar
• Nurnberg HG, Fava M, Gelenberg AJ, Hensley PL, Paine S. Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction. Int J Impot Res. 2007; 19: 167–75
   PubMed Web of Science ®Google Scholar
• Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci U S A. 2006; 103: 15124–9
   PubMedGoogle Scholar
• Teranishi KS, Slager SL, Garriock H, Kraft JB, Peters EJ, Reinalda MS, et al. Variants in PDE11A and PDE1A are not associated with citalopram response. Mol Psychiatry. 2007; 12: 1061–3
   Google Scholar
• Horvath A, Giatzakis C, Robinson-White A, Boikos S, Levine E, Griffin K, et al. Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res. 2006; 66: 11571–5
   PubMed Web of Science ®Google Scholar
• Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychosom Med. 67 Suppl 2005; 1: S26–8
   Google Scholar
• Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S, et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol. 2007; 584: 401–5
   PubMedGoogle Scholar
• Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005; 310: 1187–91
   PubMed Web of Science ®Google Scholar
• Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008; 325: 681–90
   PubMed Web of Science ®Google Scholar
• Holmans P, Weissman MM, Zubenko GS, Scheftner WA, Crowe RR, Depaulo JR, Jr, et al. Genetics of recurrent early-onset major depression (GenRED): final genome scan report. Am J Psychiatry. 2007; 164: 248–58
   PubMed Web of Science ®Google Scholar
• Licinio J, Mastronardi C, Wong ML. Pharmacogenomics of neuroimmune interactions in human psychiatric disorders. Exp Physiol. 2007; 92: 807–11
   Google Scholar
• Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999; 4: 317–27
   PubMed Web of Science ®Google Scholar